NIH-funded research P01 program project

Understanding Type 2 Diabetes, APOC3, and Heart Disease

Official title: Project 1. Type 2 diabetes, APOC3 and cardiovascular disease

Funded at University of Washington · NIH-11096556 · Data updated 2026-11-12

This work explores how a protein called APOC3 contributes to heart disease in people with type 2 diabetes.

More Diabetes research and trials

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionUniversity of Washington
NIH-funded
Lab location1 site (Seattle, United States)
Project startAugust 15, 2020
Project endJuly 31, 2030
Funding year2025
Award (this year)$633,102
NIH project number2P01HL151328-06
Project IDNIH-11096556 on NIH RePORTER

Who could benefit from this research

Could help

This foundational work is for anyone interested in the underlying causes of heart disease in type 2 diabetes, particularly those with a family history or personal experience with these conditions.

Less likely to help

Patients seeking immediate new treatments or direct clinical intervention will not find that benefit from this basic science project.

What this research studies

We know that people with type 1 or type 2 diabetes face a much higher risk of early heart disease, and this risk is partly due to how their bodies handle certain fats, not just blood sugar or LDL cholesterol. This project looks at a specific protein, APOC3, which is linked to these fats and seems to predict heart disease in people with diabetes. We are trying to understand how certain immune cells in the body influence the liver's production of APOC3 and how these APOC3-rich fats affect the cells involved in heart disease. Our goal is to uncover the exact ways APOC3 contributes to heart disease in type 2 diabetes.

Why it matters

Potential benefit: If successful, this work could lead to new ways to prevent or treat heart disease in people with diabetes by targeting APOC3 or related pathways.

How similar studies have gone: Previous work has shown that reducing APOC3 can prevent atherosclerosis in mouse models of diabetes, suggesting this is a promising area of focus.

Where this research is happening

  • University of Washington
    Seattle, United States
    Active

Researchers

  • Principal investigator: Bornfeldt, Karin E — University of Washington
  • Study coordinator: Bornfeldt, Karin E

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.